Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizer’s IBRANCE® (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer

Business Wire November 16, 2016

Pfizer Announces Results from Phase 3 OPAL Clinical Development Program Investigating XELJANZ® (Tofacitinib Citrate) for Psoriatic Arthritis

Business Wire November 15, 2016

Pfizer Prices $6,000,000,000 Debt Offering

Business Wire November 14, 2016

Pfizer Announces Tender Offer for Any and All of its 6.200% Senior Notes Due March 15, 2019

Business Wire November 14, 2016

Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers

Business Wire November 14, 2016

Landmark Study Demonstrates Pfizer’s Celebrex (Celecoxib)Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen

Business Wire November 13, 2016

Pfizer Announces Major Expansion of Humanitarian Assistance Program

Business Wire November 11, 2016

First Majestic Silver trade offers a 2.42% return in 71 days, or find similar option trades on SPDR Gold Trust, Ralph Lauren, Pfizer Inc., and Magellan Health Inc.

PR Newswire November 10, 2016

The Market In 5 Minutes: Retail Earnings Come Into Focus

Benzinga.com  November 10, 2016

Bristol-Myers Squibb and Pfizer to Deliver 12 New Eliquis® (apixaban) Presentations at American Heart Association (AHA) Scientific Sessions 2016

Business Wire November 10, 2016

IBRANCE® (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer

Business Wire November 10, 2016

Last Night's Election - A Series Of Fortunate Events For Big Pharma

Benzinga.com  November 9, 2016

Biotech Is Getting A Big Boost Following Clinton's Loss

Benzinga.com  November 9, 2016

Pfizer to Present Additional Research For XELJANZ® (Tofacitinib Citrate) In Rheumatologic Diseases, Including Rheumatoid Arthritis and Psoriatic Arthritis

Business Wire November 7, 2016

Palatin's Female Arousal Drug Data Impresses, Investors React Positively

Benzinga.com  November 3, 2016

Spark Therapeutics and Pfizer Announce Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels of Factor IX Activity

GlobeNewswire November 3, 2016

Analysts Prescribe A Downgrade For Pfizer Stock

Benzinga.com  November 2, 2016

A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead of ADP Report, Fed Decision

Benzinga.com  November 2, 2016

Pfizer’s Prevenar 13® Receives Approval For Use in Infants and Children in China

Business Wire November 2, 2016

Mid-Afternoon Market Update: Dow Falls 150 Points; Pitney Bowes Shares Down On Earnings Miss

Benzinga.com  November 1, 2016